Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands.
Value Health. 2011 Dec;14(8):1039-47. doi: 10.1016/j.jval.2011.06.008. Epub 2011 Sep 22.
To develop a stochastic population model of disease progression in chronic obstructive pulmonary disease (COPD) that includes the effects of COPD exacerbations on health-related quality of life, costs, disease progression, and mortality and can be used to assess the effects of a wide range of interventions.
The model is a multistate Markov model with time varying transition rates specified by age, sex, smoking status, COPD disease severity, and/or exacerbation type. The model simulates annual changes in COPD prevalence due to COPD incidence, exacerbations, disease progression (annual decline in the forced expiratory volume in 1 second as percentage of the predicted value), and mortality. The main outcome variables are quality-adjusted life years, total exacerbations, and COPD-related health care costs. Exacerbation-related input parameters were based on quantitative meta-analysis. All important model parameters are entered into the model as probability distributions. To illustrate the potential use of the model, costs and effects were calculated for 3-year implementation of three different COPD interventions, one pharmacologic, one on smoking cessation, and one on pulmonary rehabilitation using a time horizon of 10 years for reporting outcomes.
Compared with minimal treatment the cost/quality-adjusted life year was €8,300 for the pharmacologic intervention, €10,800 for the smoking cessation therapy, €8,700 for the combination of the pharmacologic intervention and the smoking cessation therapy, and €17,200 for the pulmonary rehabilitation program. The probability of the interventions to be cost-effective at a ceiling ratio of €20,000 varied from 58% to 100%.
The COPD model provides policy makers with information about the long-term costs and effects of interventions over the entire chain of care, from primary prevention to care for very severe COPD and includes uncertainty around the outcomes.
开发一种用于慢性阻塞性肺疾病(COPD)疾病进展的随机人群模型,该模型考虑了 COPD 加重对健康相关生活质量、成本、疾病进展和死亡率的影响,可用于评估广泛干预措施的效果。
该模型是一个多状态马尔可夫模型,其随时间变化的转移率由年龄、性别、吸烟状况、COPD 疾病严重程度和/或加重类型来确定。该模型模拟了由于 COPD 发病率、加重、疾病进展(第 1 秒用力呼气量的年下降百分比为预测值)和死亡率,COPD 的流行率每年的变化。主要的结局变量是质量调整生命年、总加重和 COPD 相关的医疗保健成本。加重相关的输入参数是基于定量荟萃分析的。所有重要的模型参数都作为概率分布输入到模型中。为了说明模型的潜在用途,使用 10 年的报告结果时间范围,计算了 3 种不同 COPD 干预措施的 3 年实施成本和效果,一种是药物干预,一种是戒烟治疗,一种是药物干预和戒烟治疗的组合。
与最低治疗相比,药物干预的成本/质量调整生命年为 8300 欧元,戒烟治疗为 10800 欧元,药物干预和戒烟治疗的组合为 8700 欧元,肺康复计划为 17200 欧元。在 20000 欧元的上限比率下,干预措施具有成本效益的概率从 58%到 100%不等。
COPD 模型为决策者提供了关于整个护理链中干预措施的长期成本和效果的信息,从初级预防到非常严重的 COPD 护理,并包括对结果的不确定性。